Aspira Women's Health (AWH) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'VERMILLION, INC.	'	'
Entity Central Index Key	'0000926617	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Common Stock, Shares Outstanding	'	35,831,776	'
Entity Public Float	'	'	$44,321,867

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$29,504	$8,007
Accounts receivable	373	137
Prepaid expenses and other current assets	372	348
Total current assets	30,249	8,492
Property and equipment, net	391	142
Total assets	30,640	8,634
Current liabilities:	'	'
Accounts payable	541	525
Accrued liabilities	1,283	1,074
Short-term debt	1,106	1,106
Deferred revenue	628	492
Total current liabilities	3,558	3,197
Long-term Deferred revenue	316	770
Total liabilities	3,874	3,967
Commitments and contingencies (Note 6)	'	'
Stockholders' equity:	'	'
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at December 31, 2013 and 2012	'	'
Common stock, $0.001 par value, 150,000,000 shares authorized; 35,825,673 and 15,200,079 shares issued and outstanding at December 31, 2013 and 2012, respectively	36	15
Additional paid-in capital	358,994	328,097
Accumulated deficit	-332,264	-323,445
Total stockholders' equity	26,766	4,667
Total liabilities and stockholders' equity	$30,640	$8,634

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Consolidated Balance Sheets [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	35,825,673	15,200,079
Common stock, shares outstanding	35,825,673	15,200,079

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations And Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Revenue:	'	'
Product	$2,112	$1,640
License	454	454
Total revenue	2,566	2,094
Cost of revenue:	'	'
Product	170	131
Total cost of revenue	170	131
Gross profit	2,396	1,963
Operating expenses:	'	'
Research and development	2,595	2,216
Sales and marketing	4,480	4,653
General and administrative	4,184	4,508
Total operating expenses	11,259	11,377
Loss from operations	-8,863	-9,414
Interest income	23	28
Interest expense	'	-206
Gain on sale of instrument business	'	1,830
Gain on litigation settlement, net	'	710
Reorganization items	'	88
Other income (expense), net	21	-182
Loss before income taxes	-8,819	-7,146
Net loss	-8,819	-7,146
Net loss per share-basic and diluted	($0.42)	($0.48)
Weighted average common shares used to compute basic and diluted net loss per common share	20,926,336	15,010,868
Net loss	-8,819	-7,146
Foreign currency translation adjustment	'	153
Comprehensive loss	($8,819)	($6,993)

Consolidated_Statements_Of_Ope1

Consolidated Statements Of Operations And Comprehensive Loss (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Research And Development [Member]	'	'
Stock-based compensation expense	$76	$127
Sales And Marketing [Member]	'	'
Stock-based compensation expense	163	203
General And Administrative [Member]	'	'
Stock-based compensation expense	$637	$965

Consolidated_Statements_Of_Cha

Consolidated Statements Of Changes In Stockholders' Equity (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Beginning Balance at Dec. 31, 2011	$15,000	$326,796,000	($316,299,000)	($153,000)	$10,359,000
Beginning Balance (in shares) at Dec. 31, 2011	14,900,831	'	'	'	'
Net loss	'	'	-7,146,000	'	-7,146,000
Foreign currency translation adjustment	'	'	'	153,000	153,000
Common stock issued in conjuntion with exercise of stock options (in shares)	8,333	'	'	'	8,333
Common stock issued in conjuntion with execise of stock options	'	6,000	'	'	6,000
Common stock issued for restricted stock awards (in shares)	290,915	'	'	'	'
Common stock issued for restricted stock awards	'	715,000	'	'	715,000
Warrants issued for services	'	14,000	'	'	14,000
Stock compensation charge	'	566,000	'	'	566,000
Ending Balance at Dec. 31, 2012	15,000	328,097,000	-323,445,000	'	4,667,000
Ending Balance (in shares) at Dec. 31, 2012	15,200,079	'	'	'	'
Net loss	'	'	-8,819,000	'	-8,819,000
Common stock and warrants issued in conjunction with private placement sale, net of issuance costs (in shares)	8,000,000	'	'	'	'
Common stock and warrants issued in conjunction with private placement sale, net of issuance costs	8,000	11,743,000	'	'	11,751,000
Common stock issued in conjuntion with exercise of stock options (in shares)	371,348	'	'	'	371,348
Common stock issued in conjuntion with execise of stock options	1,000	643,000	'	'	644,000
Warrant exercises	12,000	17,635,000	'	'	17,647,000
Warrant exercises, (in shares)	12,086,641	'	'	'	'
Common stock issued for restricted stock awards (in shares)	167,605	'	'	'	'
Common stock issued for restricted stock awards	'	361,000	'	'	361,000
Warrants issued for services	'	34,000	'	'	34,000
Stock compensation charge	'	481,000	'	'	481,000
Ending Balance at Dec. 31, 2013	$36,000	$358,994,000	($332,264,000)	'	$26,766,000
Ending Balance (in shares) at Dec. 31, 2013	35,825,673	'	'	'	'

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net loss	($8,819)	($7,146)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Foreign currency loss on liquidation	'	153
Non-cash license revenue	-454	-454
Loss on sale and disposal of property and equipment	'	2
Depreciation and amortization	72	86
Stock-based compensation expense	842	1,281
Warrants issued for services	34	14
Gain from sale of instrument business to Bio-Rad	'	-1,830
Changes in operating assets and liabilities:	'	'
Increase in accounts receivable	-236	-38
Increase in prepaid expenses and other current assets	-24	-31
Decrease in other assets	'	2
Increase (decrease) in accounts payable and accrued liabilities	225	-2,292
Increase (decrease) in deferred revenue	136	-61
Decrease in other liabilities	'	-52
Reorganization items	'	-32
Net cash used in operating activities	-8,224	-10,398
Cash flows from investing activities:	'	'
Proceeds from the sale of instrument business to Bio-Rad	'	1,830
Purchase of property and equipment	-321	-14
Net cash provided by / (used in) investing activities	-321	1,816
Cash flows from financing activities:	'	'
Principal repayment of short-term debt	'	-5,894
Proceeds from sale of common stock and warrants, net of issuance costs	11,751	'
Proceeds from exercise of common stock warrants	17,647	'
Proceeds from issuance of common stock from exercise of stock options	644	6
Net cash provided by / (used in) financing activities	30,042	-5,888
Net increase (decrease) in cash and cash equivalents	21,497	-14,470
Cash and cash equivalents, beginning of year	8,007	22,477
Cash and cash equivalents, end of year	29,504	8,007
Supplemental disclosure of cash flow information:	'	'
Cash paid during the period for interest	'	$227

Basis_Of_Presentation_And_Sign

Basis Of Presentation And Significant Accounting And Reporting Policies	12 Months Ended
	Dec. 31, 2013
Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]	'
Basis Of Presentation And Significant Accounting And Reporting Policies	'
	NOTE 1:Basis of Presentation and Summary of Significant Accounting and Reporting Policies
	Organization
	Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests in the fields of gynecologic oncology and women’s health.  In March 2010, the Company commercially launched OVA1™ ovarian tumor triage test (“OVA1”). The Company distributes OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”), which had the non-exclusive right to commercialize OVA1 on a worldwide basis, with exclusive commercialization rights in the clinical reference laboratory marketplace in each exclusive territory through September 2014, with the right to extend the exclusivity period for one additional year. These exclusive territories include the United States, India, Mexico, and the United Kingdom. The Company terminated the agreement and exclusivity with Quest Diagnostics on August 23, 2013 but the effectiveness of such termination has been disputed by Quest Diagnostics as discussed in Note 3.
	Liquidity
	On May 13, 2013, the Company completed a private placement pursuant to which existing and new investors purchased 8,000,000 shares of Vermillion common stock at a price of $1.46 per share. The Company also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. The proceeds of the private placement were $13,242,500 (net proceeds of approximately $11,751,000 after deducting offering expenses). The warrants were exercisable for 12,500,000 shares of Vermillion common stock at $1.46 per share. On December 19, 2013, warrants to purchase 12,087,000 shares were exercised and the Company received additional net proceeds of approximately $17,647,000.
	There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations.  However, management believes that the current working capital position will be sufficient to meet the Company’s working capital needs for at least the next 12 months.  Management expects cash from OVA1 sales to be the Company’s only material, recurring source of cash in 2014.
	Basis of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All intercompany transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.  The primary estimates underlying our consolidated financial statements include assumptions regarding variables used in calculating the fair value of our equity awards, income taxes and contingent liabilities.  Actual results could differ from those estimates.
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes.  Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper.  The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.
	Fair Value Measurement
	Accounting Standards Codification Topic 820 Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1 - Quoted prices in active markets for identical assets or liabilities.
	Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.
	Concentration of Credit Risk
	Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents and accounts receivable.  The Company maintains cash and cash equivalents in recognized financial institutions in the United States.  The Company has not experienced any losses associated with deposits of cash and cash equivalents.  The Company does not invest in derivative instruments or engage in hedging activities.
	Accounts receivable are derived from sales made to a  customer located in North America.  The Company performs  ongoing credit evaluations of its customer’s financial condition and generally does not require collateral.  The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable.  Accounts receivable at December 31, 2013 and 2012 and revenues for the years then ended are from one customer.
	Property and Equipment
	Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations.
	Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable.  If property and equipment are considered to be impaired, an impairment loss is recognized.
	Revenue Recognition
	Product Revenue:    The Company derives product revenues from sales of OVA1 through Quest Diagnostics.  Product revenues are recognized for tests performed when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.
	License Revenue:    Under the terms of the secured line of credit with Quest Diagnostics, portions of the borrowed principal amounts may be forgiven upon achievement of certain milestones relating to the development, regulatory approval and commercialization of certain diagnostic tests (see Note 3).  The Company accounts  for forgiveness of principal debt balances as license revenues over the term of the exclusive sales period that Quest Diagnostics received upon commercialization of an approved diagnostic test as the Company does not have a sufficient history of product sales that provides a reasonable basis for estimating future product sales. License revenue is recognized on a straight-line basis over the original remaining period of Quest Diagnostics’ sales exclusivity ending in September 2015 as Quest Diagnostics has disputed the termination of exclusivity in August 2013.
	Research and Development Costs
	Research and development costs are expensed as incurred.  Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products,  and fees paid to third parties that conduct certain research and development activities on our behalf. In addition, acquisitions of assets to be consumed in research and development are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.
	Patent Costs
	Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within selling, general and administrative expenses on the Consolidated Statements of Operations and Comprehensive Loss. Such costs aggregated approximately $475,000 and $312,000 for the years ended December 31, 2013 and 2012, respectively.
	Stock-Based Compensation
	The Company records the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to the Vermillion, Inc. Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model which requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment.
	The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding.  This data includes employees’ expected exercise and post-vesting employment termination behaviors.  The expected stock price volatility is estimated using a combination of historical and peer group volatility for a blended volatility in deriving the expected volatility assumption.  The Company made an assessment that blended volatility is more representative of future stock price trends than just using historical or peer group volatility, which corresponds to the expected life of the options.  The expected dividend yield is based on the estimated annual dividends that is expected to be paid over the expected life of the options as a percentage of the market value of our common stock as of the grant date.  The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date.  The Company uses the straight-line method to amortize the fair value over the vesting period of the award.
	The Company also records the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. The cost for these options are recalculated each reporting period using a Black-Scholes option valuation model. A change in assumptions used in the calculations, including changes in the fair value of common stock, can result in significant changes in the amounts recorded from one reporting period to another.
	Contingencies
	The Company accounts for contingencies in accordance with ASC 450 Contingencies ("ASC 450") which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Managements believes that accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.
	Income Taxes
	The Company accounts for income taxes using the liability method.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.
	ASC Topic 740, Accounting for Uncertainty in Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure.
	The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets.
	Foreign Currency Translation
	Ciphergen Biosystems KK, the Company’s Japanese subsidiary, was liquidated during 2012 and, consequently, the accumulated other comprehensive loss totaling $153,000 was recognized in the Consolidated Statement of Operations for 2012 and included in Other Expense in the Consolidated Statements of Operations and Comprehensive Loss.
	Net Loss Per Share
	Basic net loss per share is computed by dividing the net loss by the weighted average number of common stock shares outstanding during the period.  Diluted loss per share is computed by dividing the net loss by the weighted average number of common stock shares adjusted for the dilutive effect of common stock equivalent shares outstanding during the period.  Common stock equivalents consist of stock options, restricted stock units and stock warrants.  Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.
	Fair Value of Financial Instruments
	Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt.  The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies.  However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange.  The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts.  The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt are at cost, which approximates fair value due to the short maturity of those instruments.
	Segment Reporting
	The Company operates one reportable segment.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2013
Recent Accounting Pronouncements [Abstract]	'
Recent Accounting Pronouncements	'
	NOTE 2:Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) number 2013-02, Other Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income to improve the reporting of reclassifications out of accumulated other comprehensive income. ASU 2013-02 requires reporting the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income. The adoption of this ASU on January 1, 2103 did not affect the accompanying consolidated financial statements, but could require additional disclosure, if applicable, in future periods.
	In July 2013, the FASB issued ASU number 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists — a consensus of the FASB Emerging Issues Task Force. ASU 2013-11 generally requires, with some exceptions, an entity to present its unrecognized tax benefits as it relates to its net operating loss carryforwards, similar tax losses, or tax credit carryforwards, as a reduction of deferred tax assets when settlement in this regard is available under the tax law of the applicable taxing jurisdiction as of the balance sheet reporting date.  It is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. Retrospective application is permitted. The Company does not anticipate a material impact on our financial position, results of operations or cash flows as a result of this change.

Strategic_Alliance_And_Secured

Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated	12 Months Ended
	Dec. 31, 2013
Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated [Abstract]	'
Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated	'
	NOTE 3:Strategic Alliance And Secured Line Of Credit with Quest Diagnostics Incorporated
	Quest Diagnostics is a holder of the Company’s common stock. In  July 2005, the Company entered into a Strategic Alliance Agreement (as amended, the “Strategic Alliance Agreement”) with Quest Diagnostics to develop and commercialize up to three diagnostic tests from our product pipeline.  In connection with the Strategic Alliance Agreement, the Company entered into a credit agreement with Quest Diagnostics, pursuant to which Quest Diagnostics provided the Company with a $10,000,000 secured line of credit to be used to pay for certain costs and expenses related to activities under the Strategic Alliance agreement. This line of credit was collateralized by certain of our intellectual property assets. Pursuant to the Strategic Alliance Agreement, Quest Diagnostics selected two diagnostic tests to be commercialized, a peripheral arterial disease diagnostic test (differentiated from our existing program) and OVA1. The credit agreement provided for the forgiveness of portions of the amounts borrowed under the secured line of credit upon the achievement of certain milestones related to the development, regulatory approval and commercialization of certain diagnostic tests. If not otherwise forgiven, the $10,000,000 principal amount outstanding under this secured line of credit became due and payable on October 7, 2012. Through December 31, 2013, a total of $3,000,000 has been acknowledged as forgiven by Quest Diagnostics based upon milestone achievement.
	The Company believes that in September 2009 when the United States Food and Drug Administration (the “FDA”) cleared our application for a licensed laboratory test of OVA1 to be commercialized, the Company achieved a milestone under the credit agreement, resulting in a $1,000,000 reduction of the outstanding principal amount borrowed under the credit agreement.  However, Quest Diagnostics has disputed whether this milestone has been achieved.
	In September 2009, the Company achieved another milestone under the credit agreement, resulting in a $3,000,000 further reduction in the principal amount borrowed under the credit agreement.  Although the Company believed that, following this reduction, the principal balance under the line of credit was $6,000,000, the Company made monthly payments to Quest Diagnostics on the secured line of credit based on a principal balance of $7,000,000, resulting in a curtailment of the principal balance of $106,000. However, Quest Diagnostics has disputed that such additional principal curtailment was made.
	On October 12, 2012, the Company paid Quest Diagnostics approximately $5,894,000 of principal which the Company believes represented payment in full of all then outstanding principal under the secured line of credit. However, the Company continues to show the amount of the liability as $1,106,000 as of December 31, 2013 and 2012 because Quest Diagnostics has disputed that the $1,000,000 milestone was met and the $106,000 principal curtailment was made. There was no interest expense on the secured line of credit for the year ended December 31, 2013 and $206,000 of interest expense for the year ended December 31, 2012.
	Unrelated to the debt dispute described above, on May 23, 2013, the Company sent Quest Diagnostics a notice of default under the Strategic Alliance Agreement relating to a number of its material violations, breaches and failures to perform under the Strategic Alliance Agreement. The Strategic Alliance Agreement states that if a party fails to cure material defaults within 90 days of the date of the notice of default, the other party has the right to terminate the Strategic Alliance Agreement.  Quest Diagnostics has disputed the effectiveness of our notice of default. On August 23, 2013, the Company sent Quest Diagnostics a notice of termination. Notwithstanding the termination, the Company agreed that Quest Diagnostics can continue to make OVA1 available to healthcare providers on the same financial terms following the termination while negotiating in good faith towards an alternative business structure. Prior to the termination, Quest Diagnostics had the non-exclusive right to commercialize OVA1 on a worldwide basis, with exclusive commercialization rights in the clinical reference laboratory marketplace in the United States, India, Mexico, and the United Kingdom through September 2014, with the right to extend the exclusivity period for one additional year. Quest Diagnostics has disputed the effectiveness of the Company’s notice of termination.
	Accounts receivable from Quest Diagnostics totaled $373,000 and $137,000 at December 31, 2013 and 2012, respectively.

Property_And_Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2013
Property And Equipment [Abstract]	'
Property And Equipment	'
	Note 4:       Property and Equipment
	The components of property and equipment as of December 31, 2013 and 2012 were as follows:
		December 31,
	(in thousands)		2013		2012
	Machinery and equipment	$	501	$	193
	Demonstration equipment		33		33
	Computer equipment and software		116		114
	Furniture and fixtures		75		65
	Gross property and equipment		725		405
	Accumulated depreciation and amortization		-334		-263
	Property and equipment, net	$	391	$	142
	Depreciation expense for property and equipment was $72,000 and $86,000 for the years ended December 31, 2013 and 2012, respectively.

Accured_Liabilities

Accured Liabilities	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities [Abstract]	'
Accrued Liabilities	'
	NOTE 5:Accrued Liabilities
	The components of accrued liabilities as of December 31, 2013 and 2012 were as follows:
		December 31,
	(in thousands)	2013		2012
	Payroll and benefits related expenses	$	548	$	464
	Collaboration and research agreements expenses		187		133
	Professional services		262		236
	Tax-related liabilities		42		17
	Other accrued liabilities		244		224
	Total accrued liabilities	$	1,283	$	1,074

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies [Abstract]	'
Commitments And Contingencies	'
	NOTE 6:Commitments and Contingencies
	Operating Leases
	The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic oncology and women’s health. On June 1, 2010, Vermillion entered into a noncancelable operating lease for a new principal facility located in Austin, Texas. The lease includes an annual base rent of $75,000 and annual estimated common area charges, taxes and insurance of $37,000 and expires May 31, 2014.
	Rental expense under operating leases for the years ended December 31, 2013 and 2012 totaled $96,000 and $110,000, respectively.
	Noncancelable Collaboration Obligations and Other Commitments
	Vermillion has a research collaboration agreement with The Johns Hopkins University School of Medicine (“JHU”) directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human disease through March 2016.  In October 2013, Vermillion amended the research and collaboration agreement with the JHU and agreed to pay approximately $1,600,000 through June 2015 for assistance with (1) the migration of the existing OVA1 test to a new platform and (2) the development, submission and launch of a next-generation ovarian cancer diagnostic. Collaboration expenses under the JHU collaboration were $658,000 and $251,000 for the years ended December 31, 2013 and 2012, respectively.  Collaboration expenses under the JHU collaboration are included in research and development expenses.  In addition, under the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500.
	Gain on Litigation Settlement
	In February 2012, the Company entered into a settlement agreement with Oppenheimer & Co., Inc. (“Oppenheimer”) related to losses on short and long-term investments in previous years. Under the terms of the settlement agreement, the total settlement was $1,000,000  ($710,000 net after legal fees and costs), all of which was paid in 2012. The gain on litigation settlement represents recognition of the net proceeds received.
	Contingent Liabilities
	Molecular Analytical Systems, Inc. Litigation
	On July 9, 2007, Molecular Analytical Systems (“MAS”) filed a lawsuit in the Superior Court of California for the County of Santa Clara (“Superior Court”) naming Vermillion and Bio-Rad Laboratories, Inc. (“Bio-Rad”) as defendants (the “State Court lawsuit”). In connection with the State Court lawsuit, MAS alleged that the Company breached the license agreement with MAS by transferring certain Surface-Enhanced Laser Desorption/Ionization (“SELDI”) technology to Bio-Rad without obtaining MAS’s consent. MAS listed the value of its claim as in excess of $5,000,000. Thereafter, the Superior Court ordered that the dispute be arbitrated before the Judicial Arbitration and Mediation Service (“JAMS”). MAS filed its demand for arbitration in 2010 and the arbitration hearing occurred in 2011.  On February 23, 2012, an interim arbitration award was issued by the arbitrator. In the interim arbitration award, the arbitrator denied MAS’s claim for breach of the license agreement as well as several other of MAS's claims. The arbitrator found that MAS was entitled to an accounting concerning our 2% royalty obligation to MAS either through February 21, 2013 or until cumulative royalty payments reach $10 million, whichever comes first, and ordered that such royalties should be based on total GAAP revenues less revenues attributable to certain excluded entities, not just SELDI-related revenues.  Subsequently, the parties agreed to resolve (i) any and all remaining royalty obligations owed to MAS from the Company and (ii) any and all claims for fees and costs that the Company had against MAS in return for Vermillion making a one-time payment to MAS of $35,000.  The Company submitted to JAMS a mutual stipulation consistent with that agreement and the Arbitrator entered a final arbitration award incorporating that stipulation on May 21, 2012. At the Company’s request, the Superior Court (i) confirmed the final arbitration award and (ii) entered the final arbitration award as the final judgment in this case on July 26, 2012.
	Bio-Rad Laboratories, Inc. Matters
	On November 13, 2006, the Company completed the “Instrument Business Sale” to Bio-Rad. The Instrument Business Sale included the SELDI technology, ProteinChip arrays and accompanying software. Pursuant to the terms of the sales agreement, the total sales price was $20,000,000, of which $16,000,000 was paid by Bio-Rad at the closing of the transaction on November 13, 2006. A total of $4,000,000 was held back from the sales proceeds contingent upon the Company’s meeting certain obligations, of which $2,000,000 was subsequently paid and $307,000 was paid to settle certain employee termination indemnifications in fiscal 2007. From the amounts held back and interest thereon, $1,830,000 was being held in escrow as of December 31, 2011 to serve as security for the Company to fulfill certain obligations.
	In August 2009, Bio-Rad also filed a proof of claim in the bankruptcy case for indemnification of the MAS lawsuit. Management has subsequently received a final arbitration ruling from JAMS and settled the MAS claim. At the Company’s request, the Superior Court (i) confirmed the final arbitration award and (ii) entered the final arbitration award as the final judgment in this case on July 26, 2012. Thus, the Company believes that the possibility of any material loss from the indemnification of the MAS lawsuit is remote.
	In connection with the Instrument Business Sale, the Company also entered into a manufacture and supply agreement with Bio-Rad on November 13, 2006, whereby the Company agreed to purchase ProteinChip Systems and ProteinChip Arrays from Bio-Rad. In October 2009, Bio-Rad filed a proof of claim in the bankruptcy case based on certain contract claims and alleged breach of the manufacture and supply agreement for approximately $1,000,000.
	In April 2012, the Company resolved the four contract claims made by Bio-Rad arising from the Instrument Business Sale.  In exchange for a final settlement of these non-contingent claims, Bio-Rad received $700,000 from the escrow account established by the Company for the sale transaction, and the Company was returned approximately $1,080,000 from the escrow account. The final $50,000 was returned to the Company in September 2012 after final resolution of the MAS lawsuit. The Company reversed $375,000 of general and administrative expense accrued in previous periods during the year ended December 31, 2012 representing the accrued estimated liability in excess of the $700,000 settlement amount. The Company recognized the resulting gain on sale of instrument business of $1,830,000 from the release of the escrow account during the year ended December 31, 2012.
	In addition, from time to time, the Company is involved in legal proceedings and regulatory proceedings arising from operations.  The Company establishes reserves for specific liabilities in connection with legal actions that management deems to be probable and estimable.  Other than as disclosed above, the Company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the Company’s financial position or results of operations.

Common_Stock

Common Stock	12 Months Ended
	Dec. 31, 2013
Common Stock [Abstract]	'
Common Stock	'
	NOTE 7:Common Stock
	2013 Private Placement Sale
	On May 13, 2013, the Company completed a private placement pursuant to which existing and new investors purchased 8,000,000 shares of Vermillion common stock at a price of $1.46 per share. In the private placement, Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share. The proceeds of the private placement were $13,242,500 (net proceeds of approximately $11,751,000 after deducting offering expenses). The warrants were exercisable for 12,500,000 shares of common stock at $1.46 per share and expire on May 13, 2016. On December 19, 2013, certain holders of the exercised warrants to purchase 12,087,000 common shares for net proceeds of $17,647,000.
	The purchase of common stock and warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid in capital. The value ascribed to the warrants is $9,300,000 and for the common stock is $3,943,000.
	In connection with the private placement, Vermillion entered into a stockholders agreement with the purchasers named in that agreement. Pursuant to and subject to the terms of the stockholders agreement, certain of the investors received rights to participate in any future equity offerings on the same price and terms as other investors.  In addition, the stockholders agreement prohibits the Company from taking material actions without the consent of at least one of the two primary investors.  These material actions include:
		Making any acquisition with value greater than $2 million;
		Entering into, or amending the terms of agreements with Quest Diagnostics, provided that such investors’ consent shall not be unreasonably withheld, conditioned or delayed following good faith consultation with the Company;
		Submitting any resolution at a meeting of stockholders or in any other manner changing or authorizing a change in the size of the Board of Directors;
		Offering, selling or issuing any securities senior to Vermillion’s common stock or any securities that are convertible into or exchangeable or exercisable for securities ranking senior to Vermillion’s common stock;
		Amending Vermillion’s certificate of incorporation or by-laws in any manner that affects the rights, privileges or economics of Vermillion’s common stock or the warrants described above;
		Taking any action that would result in a change in control of Vermillion or an insolvency event;
		Paying or declaring dividends on any securities of the Company or distributing any assets of the Company other than in the ordinary course of business or repurchasing any outstanding securities of the Company; or
		Adopting or amending any shareholder rights plan.
	In addition, the two primary investors each received the right to designate a person to serve on Vermillion’s Board of Directors. These rights terminate for each stockholder when that stockholder ceases to beneficially own less than 50% of the shares and warrants (taking into account shares issued upon exercise of the warrants), in the aggregate, than were purchased at the closing of the private placement.
	Warrants
	Warrants outstanding as of December 31, 2013 and 2012 were as follows:
			Exercise Price	Number of Shares Outstanding under Warrant
	Issuance Date	Expiration Date	per Share	31-Dec-13	31-Dec-12
	1-Nov-11	31-Oct-13	$             3.23	-	21,000
	1-May-12	30-Apr-14	$             3.18	21,000	21,000
	1-Nov-12	31-Oct-14	$             1.93	21,000	21,000
	1-May-13	30-Apr-15	$             1.88	21,000	-
	13-May-13	13-May-16	$             1.46	413,359	-
	1-Nov-13	31-Oct-15	$             3.89	21,000	-
				497,359	63,000
	Vermillion periodically issues common stock warrants to a vendor in exchange for services. The warrants vest pro-rata on a monthly basis over a six month period and expire two years after issuance. The value of the warrants as determined by the Black-Sholes model was not significant and is classified as equity.

Loss_Per_Share

Loss Per Share	12 Months Ended
	Dec. 31, 2013
Loss Per Share [Abstract]	'
Loss Per Share	'
	NOTE 8:Loss Per Share
	The reconciliation of the numerators and denominators of basic and diluted loss per share for the years ended December 31, 2013 and 2012 was as follows:
		Loss			Shares	Per Share
	(In thousands, except per share data)	(Numerator)			(Denominator)	Amount
	Year ended December 31, 2012:
	Net loss - basic	$	-7,146		15,010,868	$	-0.48
	Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards		-		-
	Net loss - diluted	$	-7,146		15,010,868	$	-0.48
	Year ended December 31, 2013:
	Net loss - basic	$	-8,819		20,926,336	$	-0.42
	Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards		-		-
	Net loss - diluted	$	-8,819		20,926,336	$	-0.42
	Due to net losses for the years ended December 31, 2013 and 2012, diluted loss per share is calculated using the weighted average number of common shares outstanding and excludes the effects of potential common stock shares that are antidilutive.
	The potential shares of common stock that have been excluded from the diluted loss per share calculation above for the years ended December 31, 2013 and 2012 were as follows:
		Year Ended December 31,
		2013		2012
	Stock options	1,447,968		1,092,374
	Stock warrants	497,359		63,000
	Restricted stock units	1,667		8,334
	Potential common shares	1,946,994		1,163,708

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2013
Employee Benefit Plans [Abstract]	'
Employee Benefit Plans	'
	NOTE 9:Employee Benefit Plans
	2000 Stock Plan
	Under the Amended and Restated 2000 Stock Plan (the “2000 Plan”), options may be granted at prices not lower than 85% and 100% of the fair market value of the common stock for non-statutory and statutory stock options, respectively.  Options generally vest monthly over a period of four years and unexercised options generally expire ten years from the date of grant.  The authority of Vermillion’s Board of Directors to grant new stock options and awards under the 2000 Plan terminated in 2010.  Options to purchase 125,000 and 8,333 shares of common stock were exercised during the years ended December 31, 2013 and 2012, respectively. As of December 31, 2013, options to purchase 197,506 shares of common stock remained outstanding under the 2000 Plan.  No additional shares of common stock were reserved for future option grants under the 2000 Plan.
	2010 Stock Incentive Plan
	In February 2010, Vermillion’s Board of Directors approved the Amended and Restated Vermillion, Inc. 2010 Stock Incentive Plan (the “2010 Plan”). The 2010 Plan is administered by the Compensation Committee of the Board of Directors. Employees, directors, and consultants of the company are eligible to receive awards under the 2010 Plan. The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan provided for issuance of up to 1,322,983 shares of common stock, par value $0.001 per share under the 2010 Plan, subject to adjustment as provided in the 2010 Plan. On December 12, 2013, the Company’s stockholders approved an increase of 2,300,000 in the number of shares available for issuance under the 2010 Plan for a total of 3,622,983 shares. Unexercised options generally expire ten years from the date of grant. Options to purchase 246,348 shares of common stock were exercised during the year ended December 31, 2013. There were no 2010 Plan option exercises for the year ended December 31, 2012.
	During the year ended December 31, 2011, the Company awarded 177,000 shares of restricted stock from the 2010 Plan having a fair value of $724,000 to Vermillion’s executive officers.  All such restricted stock vests ratably on a quarterly basis over a three year period beginning on the vesting commencement in March 2011. The Company distributed 6,667 and 78,415 of these shares of common stock to Vermillion’s executive officers during the years ended December 31, 2013 and 2012, respectively.
	During the year ended December 31, 2013, the Company issued 160,938 shares of restricted stock from the 2010 Plan having a fair value of $334,000 to the Board of Directors as payment for services rendered in 2013. During the year ended December 31, 2012, the Company issued 212,500 shares of restricted stock from the 2010 Plan having a fair value of $414,000 to Vermillion’s Board of Directors as payment for services rendered in 2012.
	Subsequent to December 31, 2013, the Company awarded 152,000 shares of restricted stock form the 2010 Plan having a fair value of approximately $470,000 to Vermillion’s Board of Directors as payment for services in 2014.  The restricted stock vest 50% on June 1, 2014 and 25% each on September 1, 2014 and December 1, 2014.  Additionally, the Company granted 151,500 stock options with an exercise price of $2.88 per share to Vermillion’s Chairman of the Board of Directors.  The stock options vest over a four year period with 25% of the stock options vesting on December 12, 2014 and the balance in 36 equal monthly installments thereafter.  The Company also granted approximately 422,000 stock options with an exercise price of $3.09 per share to certain Vermillion officers and employees.  The stock options vest in 48 equal monthly installments.
	The activity related to shares available for grant under the 2000 Plan and 2010 Plan for the years ended December 31, 2013 and 2012  was as follows:
		2000 Stock Plan		2010 Stock Option Plan		Total
	Shares available at December 31, 2011	-		628,675		628,675
	Options canceled	251,058		136,595		387,653
	Reduction in shares reserved	-251,058		-		-251,058
	Options granted	-		-558,300		-558,300
	Restricted stock units canceled	-		28,001		28,001
	Restricted stock units granted	-		-212,500		-212,500
	Shares available at December 31, 2012	-		22,471		22,471
	Additional shares reserved	-		2,300,000		2,300,000
	Options canceled	14,150		68,908		83,058
	Reduction in shares reserved	-14,150		-		-14,150
	Options granted	-		-810,000		-810,000
	Restricted stock units granted	-		-160,938		-160,938
	Shares available at December 31, 2013	-		1,420,441		1,420,441
	The stock option activity under the 2000 Plan and 2010 Plan for the years ended December 31, 2013 and 2012 was as follows:
		Number of Shares		Weighted Average Exercise Price			Aggregate Intrinsic Value			Weighted Average Remaining Contractual  Term
	Options outstanding at December 31, 2011	930,060		$	12.97		$	16		5.90
	Granted	558,300			1.54
	Exercised	-8,333			0.75
	Canceled	-387,653			21.57
	Options outstanding at December 31, 2012	1,092,374		$	4.17		$	20		6.23
	Granted	810,000			2.05
	Exercised	-371,348			1.63
	Canceled	-83,058			8.66
	Options outstanding at December 31, 2013	1,447,968		$	3.36		$	780		7.94
	Shares exercisable:
	31-Dec-13	614,439		$	5.09		$	297		6.23
	Shares expected to vest:
	31-Dec-13	683,494		$	2.08		$	483		9.21
	The range of exercise prices for options outstanding and exercisable at December 31, 2013 is as follows:
		Exercise Price					Options Outstanding			Weighted  Average Exercise Price	Weighted Average  Remaining Life in Years	Options Exercisable		Weighted Average Exercise Price
	$	0.01	-	$	1.22		415,000		$	1.21	9.08	87,499	$	1.15
		1.23	-		1.62		250,012		$	1.62	8.22	190,902	$	1.62
		1.63	-		2.7		371,209			2.05	8.14	138,172		2.00
		2.71	-		9.92		301,949			4.23	8.13	89,280		6.19
		9.93	-		29.6		109,798			17.44	1.83	108,586		17.41
	$	0.01	-	$	29.6		1,447,968		$	3.36	7.94	614,439	$	5.09
	(in thousands)		Total Intrinsic Value of Options Exercised			Total Fair Value of Vested Options
	Year ended December 31, 2013	$	291		$	550
	Year ended December 31, 2012	$	7		$	525
	Stock-based Compensation
	Employee Stock-based Compensation Expense
	The assumptions used to calculate the fair value of options granted under the 2010 Plan that were incorporated in the Black-Scholes pricing model for the years ended December 31, 2013 and 2012 were as follows:
		Year Ended December 31,
		2013				2012
	Dividend yield		-	%			-	%
	Volatility		79	%			78	%
	Risk-free interest rate		1.91	%			1.32	%
	Expected lives (years)		6.0				6.0
	Weighted average fair value	$	1.50			$	1.04
	The allocation of stock-based compensation expense by functional area for the years ended December 31, 2013 and 2012 was as follows:
		Year Ended December 31,
	(in thousands)		2013		2012	2012
	Research and development	$	74		$	112
Sales and marketing		163			203
General and administrative		602			942
Total	$	839		$	1,257
The Company has a 100% valuation allowance recorded against our deferred tax assets and as a result of ASC 718 had no effect on income tax expense in the Consolidated Statement of Operations or the Consolidated Statement of Cash Flows.  As of December 31, 2013, total unrecognized compensation cost related to nonvested stock option awards was approximately $1,233,000 and the related weighted average period over which it is expected to be recognized was 2.14 years.
401(k)Plan
The Company’s 401(k) Plan allows eligible employees to defer up to an annual limit of the lesser of 90.0% of eligible compensation or a maximum contribution amount subject to the Internal Revenue Service annual contribution limit.  The Company is not required to make contributions under the 401(k) Plan.  During the years ended December 31, 2013 and 2012,  the Company did not contribute to the 401(k) Plan.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	NOTE 10:Income Taxes
	Domestic and foreign components of loss before income taxes for the years ended December 31, 2013 and 2012 were as follows:
		Year Ended December 31,
	(in thousands)		2013		2012
	Domestic	$	-8,819		$	-7,052
	Foreign		-			-94
		$	-8,819		$	-7,146
	Based on the available objective evidence, management believes it is more likely than not that the net deferred tax assets will not be fully realizable due to the history of our operating losses.  Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets at December 31, 2013 and 2012. There was no income tax expense or benefit for the years ended December 31, 2013 or 2012.
	The components of deferred tax assets (liabilities) at December 31, 2013 and 2012 were as follows:
		Year Ended December 31,
	(in thousands)	2013			2012
	Deferred tax assets:
	Depreciation and amortization	$	8,698		$	8,955
	Other		1,651			1,431
	Net operating losses		54,005			46,918
	Total deferred tax assets		64,354			57,304
	Valuation allowance		-64,346			-57,296
	Net deferred tax assets	$	8		$	8
	Deferred tax liabilities:
	Other	$	-8		$	-8
	Total deferred tax liabilities	$	-8		$	-8
	Net deferred tax asset (liability)	$	-		$	-
	The reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2013 and 2012 was as follows:
		Year Ended December 31,
		2013			2012
	Tax at federal statutory rate	34	%		34	%
	State tax, net of federal benefit	2			3
	Valuation allowance	-39			-31
	Change in warrant valuation	-			-
	Net operating loss and credit reduction due to section 382 limitations	-			-35
	Permanent items	-1			25
	Other	4			4
	Effective income tax rate	-	%		-	%
	As of December 31, 2013,  the Company had a net operating loss of approximately $146,000,000 for federal and $121,000,000 for state tax purposes.  If not utilized, these carryforwards will begin to expire beginning in 2025 for federal purposes and 2016 for state purposes. As of December 31, 2012,  the Company had a net operating loss of approximately $133,000,000 for federal and $105,000,000 for state tax purposes.
	The Company’s ability to use net operating loss credit carryforwards may be restricted due to ownership change limitations occurring in the past or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986 (“Section 382”), as amended, as well as similar state provisions. These ownership changes may also limit the amount of net operating loss credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively.
	The Company believes that Section 382 ownership changes occurred as a result of the follow-on public common stock offering in 2011 and 2013. Any limitation may result in the expiration of a portion of the net operating loss credit carryforwards before utilization and any net operating loss credit carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. Due to the existence of a valuation allowance, it is not expected that such limitations, if any, will have an impact on the results of operations or financial position.
	The Company has provided a full valuation allowance on the deferred tax assets relating to deferred tax assets.  The valuation allowance was $64,000,000 and $57,000,000 at December 31, 2013 and 2012, respectively. The increase of $7,000,000 between 2013 and 2012 is primarily due to adjustments to the domestic deferred tax assets relating to net operating losses.
	The Company files income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. The Company has not been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December 31, 2013,  the federal returns for the years ended 2010 through the current period and most state returns for the years ended 2009 through the current period are still open to examination. In addition, all of the net operating losses and research and development credits generated in years earlier than 2010 and 2009, respectively, are still subject to Internal Revenue Service audit. The federal and California tax returns for the year ended December 31, 2012 reflect research and development carryforwards of $5,655,000 and $5,242,000, respectively. The Company has recognized additional deferred tax assets for federal and California research and development credits of $72,000 and $54,000 for the year ended December 31, 2013, respectively.  As of December 31, 2013,  gross unrecognized tax benefits are approximately $10,064,000 which are attributable to research and development credits.  A reconciliation of the change in unrecognized tax benefits is as follows:
	(in thousands)			Federal Tax			State Tax		Total
	Balance at December 31, 2011		$	5,586		$	5,191	$	10,777
	Increase in tax position during 2012			69			51		120
	Balance at December 31, 2012		$	5,655		$	5,242	$	10,897
	Increase in tax position during 2013			72			54		126
	Decrease due to expirations			-687			-272		-959
	Balance at December 31, 2013		$	5,040		$	5,024	$	10,064
	The increase for the year ended December 31, 2013 relates to a tax position taken during the current year. The increase for the year ended December 31, 2012 is related to tax positions taken during 2012 and prior years. If the $11,000,000 of unrecognized income tax benefit is recognized, approximately $11,000,000 would impact the effective tax rate in the period in which each of the benefits is recognized.
	No interest or penalties as a result of uncertain tax positions have been recorded as of December 31, 2013 and 2012.  Accrued interest and penalties would be included within the related liability in the Consolidated Balance Sheet.

Other_Related_Party_Transactio

Other Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Other Related Party Transactions [Abstract]	'
Other Related Party Transactions	'
	NOTE 11:Other Related Party Transactions
	Consulting Agreements
	On March 18, 2013, the Company entered into a short term consulting agreement for transition services with Mr. Huebner (the “2013 Consulting Agreement”). Pursuant to the terms of the 2013 Consulting Agreement, Mr. Huebner assisted in the integration and transition of the new President and Chief Executive Officer. Mr. Huebner was paid a total of $45,000 during the three month term of the Consulting Agreement, which expired in June 2013.
	On December 3, 2012,  the Company entered into a consulting agreement with the former President and Chief Executive Officer and director, Gail S. Page. Pursuant to the terms of the consulting agreement, Ms. Page assisted the Company as needed, including providing advice and recommendations with respect to the development and commercialization of the Company’s existing and future diagnostic tests, and managing and developing relationships with existing and future collaborators and partners. In consideration for such services, Ms. Page was paid a monthly fee of $18,000. For the years ended December 31, 2013 and 2012, the total amount of consulting fee expense to Ms. Page was $45,000 and $18,000, respectively.  The consulting agreement was terminated with an effective date of March 15, 2013.
	On March 1, 2012,  the Company entered into a consulting agreement with the former Vice President of Strategy, who resigned effective February 29, 2012.  Pursuant to the terms of the consulting agreement, the former Vice President of Strategy provided consulting services. This consulting agreement was terminated in June 2012. For the year ended December 31, 2012, the total amount of consulting fee expense to the former Vice President of Strategy was $23,000 and the fair value of continued vesting in restricted stock was $1,000 until the termination of the consulting agreement.
	In November 2011, the Company entered into a consulting agreement with its former Senior Vice President and Chief Science Officer,  Eric T. Fung, M.D., Ph.D.  Pursuant to the terms of the consulting agreement, Dr. Fung served as the Chief Medical Officer and a member of the Scientific Advisory Board. Dr. Fung’s consulting agreement and Scientific Advisory Board services were terminated in June 2012. For the year ended December 31, 2012, the total amount of consulting fee expense for Dr. Fung was $27,000. During 2012, Dr. Fung also continued to vest in restricted stock with a fair value of $11,000 until the termination of the consulting agreement.
	On June 17, 2011, the Company entered into a consulting agreement with Bruce A. Huebner, a member of the Board of Directors until December 12, 2013.  Pursuant to the terms of the consulting agreement, Mr. Huebner provided consulting services regarding sales, marketing, business development and corporate strategy.  For the year ended December 31, 2012, the total amount of consulting fees paid to Mr. Huebner was $5,000.  On November 27, 2012, the Company announced the appointment of Mr. Huebner as Interim Chief Executive Officer. Mr. Huebner served in this position until the appointment of Thomas McLain as President and Chief Executive officer on March 18, 2013.

Basis_Of_Presentation_And_Sign1

Basis Of Presentation And Significant Accounting And Reporting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]	'
Organization	'
	Organization
	Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests in the fields of gynecologic oncology and women’s health.  In March 2010, the Company commercially launched OVA1™ ovarian tumor triage test (“OVA1”). The Company distributes OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”), which had the non-exclusive right to commercialize OVA1 on a worldwide basis, with exclusive commercialization rights in the clinical reference laboratory marketplace in each exclusive territory through September 2014, with the right to extend the exclusivity period for one additional year. These exclusive territories include the United States, India, Mexico, and the United Kingdom. The Company terminated the agreement and exclusivity with Quest Diagnostics on August 23, 2013 but the effectiveness of such termination has been disputed by Quest Diagnostics as discussed in Note 3.
Liquidity	'
	Liquidity
	On May 13, 2013, the Company completed a private placement pursuant to which existing and new investors purchased 8,000,000 shares of Vermillion common stock at a price of $1.46 per share. The Company also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. The proceeds of the private placement were $13,242,500 (net proceeds of approximately $11,751,000 after deducting offering expenses). The warrants were exercisable for 12,500,000 shares of Vermillion common stock at $1.46 per share. On December 19, 2013, warrants to purchase 12,087,000 shares were exercised and the Company received additional net proceeds of approximately $17,647,000.
	There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations.  However, management believes that the current working capital position will be sufficient to meet the Company’s working capital needs for at least the next 12 months.  Management expects cash from OVA1 sales to be the Company’s only material, recurring source of cash in 2014.
Basis Of Consolidation	'
	Basis of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All intercompany transactions have been eliminated in consolidation
Use Of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.  The primary estimates underlying our consolidated financial statements include assumptions regarding variables used in calculating the fair value of our equity awards, income taxes and contingent liabilities.  Actual results could differ from those estimates.
Cash And Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes.  Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper.  The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.
Fair Value Measurement	'
	Fair Value Measurement
	Accounting Standards Codification Topic 820 Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1 - Quoted prices in active markets for identical assets or liabilities.
	Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.
Concentration Of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents and accounts receivable.  The Company maintains cash and cash equivalents in recognized financial institutions in the United States.  The Company has not experienced any losses associated with deposits of cash and cash equivalents.  The Company does not invest in derivative instruments or engage in hedging activities.
	Accounts receivable are derived from sales made to a  customer located in North America.  The Company performs  ongoing credit evaluations of its customer’s financial condition and generally does not require collateral.  The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable.  Accounts receivable at December 31, 2013 and 2012 and revenues for the years then ended are from one customer.
Property And Equipment	'
	Property and Equipment
	Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations.
	Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable.  If property and equipment are considered to be impaired, an impairment loss is recognized.
Revenue Recognition	'
	Revenue Recognition
	Product Revenue:    The Company derives product revenues from sales of OVA1 through Quest Diagnostics.  Product revenues are recognized for tests performed when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.
	License Revenue:    Under the terms of the secured line of credit with Quest Diagnostics, portions of the borrowed principal amounts may be forgiven upon achievement of certain milestones relating to the development, regulatory approval and commercialization of certain diagnostic tests (see Note 3).  The Company accounts  for forgiveness of principal debt balances as license revenues over the term of the exclusive sales period that Quest Diagnostics received upon commercialization of an approved diagnostic test as the Company does not have a sufficient history of product sales that provides a reasonable basis for estimating future product sales. License revenue is recognized on a straight-line basis over the original remaining period of Quest Diagnostics’ sales exclusivity ending in September 2015 as Quest Diagnostics has disputed the termination of exclusivity in August 2013.
Research And Development Costs	'
	Research and Development Costs
	Research and development costs are expensed as incurred.  Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products,  and fees paid to third parties that conduct certain research and development activities on our behalf. In addition, acquisitions of assets to be consumed in research and development are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.
Patent Costs	'
	Patent Costs
	Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within selling, general and administrative expenses on the Consolidated Statements of Operations and Comprehensive Loss. Such costs aggregated approximately $475,000 and $312,000 for the years ended December 31, 2013 and 2012, respectively.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company records the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to the Vermillion, Inc. Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model which requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment.
	The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding.  This data includes employees’ expected exercise and post-vesting employment termination behaviors.  The expected stock price volatility is estimated using a combination of historical and peer group volatility for a blended volatility in deriving the expected volatility assumption.  The Company made an assessment that blended volatility is more representative of future stock price trends than just using historical or peer group volatility, which corresponds to the expected life of the options.  The expected dividend yield is based on the estimated annual dividends that is expected to be paid over the expected life of the options as a percentage of the market value of our common stock as of the grant date.  The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date.  The Company uses the straight-line method to amortize the fair value over the vesting period of the award.
	The Company also records the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. The cost for these options are recalculated each reporting period using a Black-Scholes option valuation model. A change in assumptions used in the calculations, including changes in the fair value of common stock, can result in significant changes in the amounts recorded from one reporting period to another.
Contingencies	'
	Contingencies
	The Company accounts for contingencies in accordance with ASC 450 Contingencies ("ASC 450") which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Managements believes that accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes using the liability method.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.
	ASC Topic 740, Accounting for Uncertainty in Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure.
	The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets.
Foreign Currency Translation	'
	Foreign Currency Translation
	Ciphergen Biosystems KK, the Company’s Japanese subsidiary, was liquidated during 2012 and, consequently, the accumulated other comprehensive loss totaling $153,000 was recognized in the Consolidated Statement of Operations for 2012 and included in Other Expense in the Consolidated Statements of Operations and Comprehensive Loss.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is computed by dividing the net loss by the weighted average number of common stock shares outstanding during the period.  Diluted loss per share is computed by dividing the net loss by the weighted average number of common stock shares adjusted for the dilutive effect of common stock equivalent shares outstanding during the period.  Common stock equivalents consist of stock options, restricted stock units and stock warrants.  Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.
Fair Value Of Financial Instruments	'
	Fair Value of Financial Instruments
	Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt.  The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies.  However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange.  The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts.  The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt are at cost, which approximates fair value due to the short maturity of those instruments.
Segment Reporting	'
	Segment Reporting
	The Company operates one reportable segment.

Property_And_Equipment_Tables

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property And Equipment [Abstract]	'
Components Of Property And Equipment	'
		December 31,
	(in thousands)		2013		2012
	Machinery and equipment	$	501	$	193
	Demonstration equipment		33		33
	Computer equipment and software		116		114
	Furniture and fixtures		75		65
	Gross property and equipment		725		405
	Accumulated depreciation and amortization		-334		-263
	Property and equipment, net	$	391	$	142

Accurued_Liabilities_Tables

Accurued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities [Abstract]	'
Components Of Accrued Liabilities	'
		December 31,
	(in thousands)	2013		2012
	Payroll and benefits related expenses	$	548	$	464
	Collaboration and research agreements expenses		187		133
	Professional services		262		236
	Tax-related liabilities		42		17
	Other accrued liabilities		244		224
	Total accrued liabilities	$	1,283	$	1,074

Common_Stock_Tables

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2013
Common Stock [Abstract]	'
Schedule Of Warrants Outstanding	'
			Exercise Price	Number of Shares Outstanding under Warrant
	Issuance Date	Expiration Date	per Share	31-Dec-13	31-Dec-12
	1-Nov-11	31-Oct-13	$             3.23	-	21,000
	1-May-12	30-Apr-14	$             3.18	21,000	21,000
	1-Nov-12	31-Oct-14	$             1.93	21,000	21,000
	1-May-13	30-Apr-15	$             1.88	21,000	-
	13-May-13	13-May-16	$             1.46	413,359	-
	1-Nov-13	31-Oct-15	$             3.89	21,000	-
				497,359	63,000

Loss_Per_Share_Tables

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Loss Per Share [Abstract]	'
Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share	'
		Loss			Shares	Per Share
	(In thousands, except per share data)	(Numerator)			(Denominator)	Amount
	Year ended December 31, 2012:
	Net loss - basic	$	-7,146		15,010,868	$	-0.48
	Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards		-		-
	Net loss - diluted	$	-7,146		15,010,868	$	-0.48
	Year ended December 31, 2013:
	Net loss - basic	$	-8,819		20,926,336	$	-0.42
	Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards		-		-
	Net loss - diluted	$	-8,819		20,926,336	$	-0.42
Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation	'
		Year Ended December 31,
		2013		2012
	Stock options	1,447,968		1,092,374
	Stock warrants	497,359		63,000
	Restricted stock units	1,667		8,334
	Potential common shares	1,946,994		1,163,708

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Employee Benefit Plans [Abstract]	'
Activity Related to Shares Available for Grant Under the 2000 Plan and 2010 Plan	'
		2000 Stock Plan		2010 Stock Option Plan		Total
	Shares available at December 31, 2011	-		628,675		628,675
	Options canceled	251,058		136,595		387,653
	Reduction in shares reserved	-251,058		-		-251,058
	Options granted	-		-558,300		-558,300
	Restricted stock units canceled	-		28,001		28,001
	Restricted stock units granted	-		-212,500		-212,500
	Shares available at December 31, 2012	-		22,471		22,471
	Additional shares reserved	-		2,300,000		2,300,000
	Options canceled	14,150		68,908		83,058
	Reduction in shares reserved	-14,150		-		-14,150
	Options granted	-		-810,000		-810,000
	Restricted stock units granted	-		-160,938		-160,938
	Shares available at December 31, 2013	-		1,420,441		1,420,441
Stock Option Activity Under 2000 Plan and 2010 Plan	'
		Number of Shares		Weighted Average Exercise Price			Aggregate Intrinsic Value			Weighted Average Remaining Contractual  Term
	Options outstanding at December 31, 2011	930,060		$	12.97		$	16		5.90
	Granted	558,300			1.54
	Exercised	-8,333			0.75
	Canceled	-387,653			21.57
	Options outstanding at December 31, 2012	1,092,374		$	4.17		$	20		6.23
	Granted	810,000			2.05
	Exercised	-371,348			1.63
	Canceled	-83,058			8.66
	Options outstanding at December 31, 2013	1,447,968		$	3.36		$	780		7.94
	Shares exercisable:
	31-Dec-13	614,439		$	5.09		$	297		6.23
	Shares expected to vest:
	31-Dec-13	683,494		$	2.08		$	483		9.21
Range of Exercise Prices for Options Outstanding and Exercisable	'
		Exercise Price					Options Outstanding			Weighted  Average Exercise Price	Weighted Average  Remaining Life in Years	Options Exercisable		Weighted Average Exercise Price
	$	0.01	-	$	1.22		415,000		$	1.21	9.08	87,499	$	1.15
		1.23	-		1.62		250,012		$	1.62	8.22	190,902	$	1.62
		1.63	-		2.7		371,209			2.05	8.14	138,172		2.00
		2.71	-		9.92		301,949			4.23	8.13	89,280		6.19
		9.93	-		29.6		109,798			17.44	1.83	108,586		17.41
	$	0.01	-	$	29.6		1,447,968		$	3.36	7.94	614,439	$	5.09
Fair Value of Options Vested	'
	(in thousands)		Total Intrinsic Value of Options Exercised			Total Fair Value of Vested Options
	Year ended December 31, 2013	$	291		$	550
	Year ended December 31, 2012	$	7		$	525
Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan	'
		Year Ended December 31,
		2013				2012
	Dividend yield		-	%			-	%
	Volatility		79	%			78	%
	Risk-free interest rate		1.91	%			1.32	%
	Expected lives (years)		6.0				6.0
	Weighted average fair value	$	1.50			$	1.04
Allocation of Stock-Based Compensation Expense by Functional Area	'
		Year Ended December 31,
	(in thousands)		2013		2012	2012
	Research and development	$	74		$	112
	Sales and marketing		163			203
	General and administrative		602			942
	Total	$	839		$	1,257

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Domestic And Foreign Components Of Loss Before Income Taxes	'
		Year Ended December 31,
	(in thousands)		2013		2012
	Domestic	$	-8,819		$	-7,052
	Foreign		-			-94
		$	-8,819		$	-7,146
Components Of Deferred Tax Assets (Liabilities)	'
		Year Ended December 31,
	(in thousands)	2013			2012
	Deferred tax assets:
	Depreciation and amortization	$	8,698		$	8,955
	Other		1,651			1,431
	Net operating losses		54,005			46,918
	Total deferred tax assets		64,354			57,304
	Valuation allowance		-64,346			-57,296
	Net deferred tax assets	$	8		$	8
	Deferred tax liabilities:
	Other	$	-8		$	-8
	Total deferred tax liabilities	$	-8		$	-8
	Net deferred tax asset (liability)	$	-		$	-
Reconciliation Of Statutory Federal Income Tax Rate	'
		Year Ended December 31,
		2013			2012
	Tax at federal statutory rate	34	%		34	%
	State tax, net of federal benefit	2			3
	Valuation allowance	-39			-31
	Change in warrant valuation	-			-
	Net operating loss and credit reduction due to section 382 limitations	-			-35
	Permanent items	-1			25
	Other	4			4
	Effective income tax rate	-	%		-	%
Reconciliation Of Change In Unrecognized Tax Benefits	'
	(in thousands)			Federal Tax			State Tax		Total
	Balance at December 31, 2011		$	5,586		$	5,191	$	10,777
	Increase in tax position during 2012			69			51		120
	Balance at December 31, 2012		$	5,655		$	5,242	$	10,897
	Increase in tax position during 2013			72			54		126
	Decrease due to expirations			-687			-272		-959
	Balance at December 31, 2013		$	5,040		$	5,024	$	10,064

Basis_Of_Presentation_And_Sign2

Basis Of Presentation And Significant Accounting And Reporting Policies (Details) (USD $)	12 Months Ended			0 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 19, 2013	13-May-13	Dec. 31, 2013	Dec. 31, 2013
	segment			Private Placement [Member]	Private Placement [Member]	Minimum [Member]	Maximum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'
Common stock, shares issued	35,825,673	15,200,079	'	'	8,000,000	'	'
Price per share	$0.00	$0.00	'	'	$1.46	'	'
Issued a warrant to purchase common stock with an exercise price	'	'	'	'	$0.13	'	'
Proceeds from issuance of private placement	$11,751,000	'	'	'	$13,242,500	'	'
Net proceeds from issuance of private placement	'	'	'	'	11,751,000	'	'
Warrants outstanding to purchase shares	497,359,000	63,000,000	'	'	12,500,000	'	'
Exercise price of warrants	'	'	'	'	1.46	'	'
Shares of common stock called by warrants upon exercise of warrants	'	'	'	12,087,000	'	'	'
Value of warrants	17,647,000	'	'	17,647,000	'	'	'
Useful life	'	'	'	'	'	'3 years	'5 years
Accumulated deficit	-332,264,000	-323,445,000	'	'	'	'	'
Total stockholders' equity	26,766,000	4,667,000	10,359,000	'	'	'	'
Cash and cash equivalents	29,504,000	8,007,000	22,477,000	'	'	'	'
Current liabilities	3,558,000	3,197,000	'	'	'	'	'
License revenue recognized	454,000	454,000	'	'	'	'	'
Patent costs	475,000	312,000	'	'	'	'	'
Foreign currency translation adjustment included in AOCI	'	153,000	'	'	'	'	'
Proceeds from warrants issue in connection with private placement	$17,647,000	'	'	'	'	'	'
Number of reportable segments	1	'	'	'	'	'	'

Strategic_Alliance_And_Secured1

Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated (Details) (USD $)	0 Months Ended		1 Months Ended		12 Months Ended
	Oct. 12, 2013	Oct. 12, 2012	Sep. 30, 2009	Jul. 31, 2005	Dec. 31, 2013	Dec. 31, 2012
				item
Line of Credit Facility [Line Items]	'	'	'	'	'	'
Line of Credit Facility Additional Reduction In Outstanding Principal Balance	'	'	$3,000,000	'	'	'
Secured line of credit, liability	'	'	'	'	1,106,000	1,106,000
Selected To Commercialize [Member]	'	'	'	'	'	'
Line of Credit Facility [Line Items]	'	'	'	'	'	'
Number of diagnostics tests	'	'	'	2	'	'
Quest Diagnostics [Member]	'	'	'	'	'	'
Line of Credit Facility [Line Items]	'	'	'	'	'	'
Quest Diagnostics provided secured line of credit	'	'	'	10,000,000	'	'
Number of diagnostics tests	'	'	'	3	'	'
Line of Credit Facility Additional Reduction In Outstanding Principal Balance	'	'	1,000,000	'	'	'
Line of Credit, reduction in principal amount	'	'	'	'	3,000,000	'
Outstanding principal balance of secured line of credit after additional reduction	'	'	6,000,000	'	'	'
Line of Credit, outstanding principal balance	'	'	7,000,000	'	'	'
Line of credit, interest expense	'	'	'	'	0	206,000
Payments made in excess of interest towards principal	106,000	5,894,000	106,000	'	'	'
Secured line of credit, liability	'	'	'	'	1,106,000	1,106,000
Accounts receivable, Quest Diagnostics	'	'	'	'	$373,000	$137,000,000

Property_And_Equipment_Narrati

Property And Equipment (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property And Equipment [Abstract]	'	'
Depreciation expense for property and equipment	$72,000	$86,000

Property_And_Equipment_Compone

Property And Equipment (Components Of Property And Equipment) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	$725	$405
Accumulated depreciation and amortization	-334	-263
Property and equipment, net	391	142
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	501	193
Demonstration Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	33	33
Computer Equipment And Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	116	114
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross property and equipment	$75	$65

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]	'	'
Payroll and benefits related expenses	$548	$464
Collaboration and research agreements expenses	187	133
Professional services	262	236
Tax-related liabilities	42	17
Other accrued liabilities	244	224
Total accrued liabilities	$1,283	$1,074

Commitments_And_Contingencies_

Commitments And Contingencies (Details) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Nov. 13, 2006

Feb. 29, 2012

Oct. 31, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2007

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Nov. 13, 2006

Dec. 31, 2012

Sep. 30, 2012

Apr. 30, 2012

Dec. 31, 2013

Johns Hopkins University School of Medicine

Johns Hopkins University School of Medicine

Johns Hopkins University School of Medicine

Bio-Rad

Bio-Rad

Bio-Rad

Bio-Rad

Austin, Texas Facility [Member]

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual base rent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$75,000

Annual estimated common area charges, taxes and insurance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

37,000

Operating leases rental expense

'

'

'

96,000

110,000

'

'

'

'

'

'

'

'

'

'

Payment for research

'

'

'

'

'

'

'

1,600,000

'

'

'

'

'

'

'

Collaboration Expenses

'

'

'

'

'

'

'

'

658,000

251,000

'

'

'

'

'

Percent of royalty paid

'

'

'

'

'

'

'

'

4.00%

'

'

'

'

'

'

Minimum royalty payment

'

'

'

'

'

'

'

'

57,500

'

'

'

'

'

'

Total settlement

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Net amount received by the Company

'

710,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Claim for license agreement

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

Claims for fees and costs

'

'

'

35,000

'

'

'

'

'

'

'

'

'

'

'

Royalty obligation to MAS

'

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

Cumulative royalty payments

'

'

'

10

'

'

'

'

'

'

'

'

'

'

'

Total sales price

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

Payment for Closing Sales Agreement

'

'

'

'

'

'

'

'

'

'

16,000,000

'

'

'

'

Sales proceeds contingent

2,000,000

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

Claim for indemnification

'

'

'

'

'

'

307,000

'

'

'

'

'

'

'

'

Contract claims

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Non-contingent claims

'

'

'

'

'

'

'

'

'

'

'

'

'

700,000

'

Sale transaction return from the escrow account

'

'

'

'

'

1,830,000

'

'

'

'

'

'

'

1,080,000

'

Contingent indemnity claim

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

Reversal of general and administrative expense accrued

'

'

'

'

'

'

'

'

'

'

'

375,000

'

'

'

Gain on sale of instrument business

'

'

'

'

$1,830,000

'

'

'

'

'

'

$1,830,000

'

'

'

Common_Stock_Narrative_Details

Common Stock (Narrative) (Details) (USD $)	12 Months Ended		0 Months Ended			0 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 19, 2013	13-May-13	Dec. 31, 2013	13-May-13	Dec. 31, 2013
			Private Placement [Member]	Private Placement [Member]	Private Placement [Member]	General And Administrative [Member]	Stock Warrants [Member]
Common Stock Equity [Line Items]	'	'	'	'	'	'	'
Common stock, shares issued	35,825,673	15,200,079	'	8,000,000	'	'	'
Price per share	$0.00	$0.00	'	$1.46	'	'	'
Proceeds from issuance of private placement	$11,751,000	'	'	$13,242,500	'	$13,242,500	'
Net proceeds from issuance of private placement	'	'	'	11,751,000	'	'	'
Shares of common stock called by warrants upon exercise of warrants	'	'	12,087,000	'	'	'	'
Exercise price of warrants	'	'	'	1.46	'	'	'
Value of warrants	17,647,000	'	17,647,000	'	'	'	'
Issued a warrant to purchase common stock with an exercise price	'	'	'	$0.13	'	'	'
Fair value of warrants issued	'	'	'	'	9,300,000	'	'
Common stock value	36,000	15,000	'	'	3,943,000	'	'
Warrants outstanding to purchase shares	497,359,000	63,000,000	'	12,500,000	'	'	'
Maximum acquisition	$2,000,000	'	'	'	'	'	'
Vesting period	'	'	'	'	'	'	'6 months
Warrants expiration	'2 years	'	'	'	'	'	'

Common_Stock_Schedule_Of_Warra

Common Stock (Schedule Of Warrants Outstanding) (Details)	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]	'	'
Number of Shares Outstanding under Warrant	497,359,000	63,000,000
Period 1 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Issuance Date	1-Nov-11	'
Expiration Date	31-Oct-13	'
Exercise Price per Share	3.23	'
Number of Shares Outstanding under Warrant	'	21,000,000
Period 2 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Issuance Date	1-May-12	'
Expiration Date	30-Apr-14	'
Exercise Price per Share	3.18	'
Number of Shares Outstanding under Warrant	21,000,000	21,000,000
Period 3 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Issuance Date	1-Nov-12	'
Expiration Date	31-Oct-14	'
Exercise Price per Share	1.93	'
Number of Shares Outstanding under Warrant	21,000,000	21,000,000
Period 4 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Issuance Date	1-May-13	'
Expiration Date	30-Apr-15	'
Exercise Price per Share	1.88	'
Number of Shares Outstanding under Warrant	21,000,000	'
Period 5 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Issuance Date	13-May-13	'
Expiration Date	13-May-16	'
Exercise Price per Share	1.46	'
Number of Shares Outstanding under Warrant	413,359,000	'
Period 6 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Issuance Date	1-Nov-13	'
Expiration Date	31-Oct-15	'
Exercise Price per Share	3.89	'
Number of Shares Outstanding under Warrant	21,000,000	'

Loss_Per_Share_Reconciliation_

Loss Per Share (Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Loss Per Share [Abstract]	'	'
Net loss-basic	($8,819)	($7,146)
Net loss-diluted	($8,819)	($7,146)
Net loss-basic	20,926,336	15,010,868
Net loss-diluted	20,926,336	15,010,868
Basic Per Share Amount	($0.42)	($0.48)
Diluted Per Share Amount	($0.42)	($0.48)

Loss_Per_Share_Potential_Share

Loss Per Share (Potential Shares Of Common Stock) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share	1,946,994	1,163,708
Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share	1,447,968	1,092,374
Stock Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share	497,359	63,000
Restricted Stock Units [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share	1,667	8,334

Employee_Benefits_Plans_Narrat

Employee Benefits Plans (Narrative) (Details) (USD $)

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 12, 2013

Dec. 31, 2013

Dec. 31, 2012

Feb. 28, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 01, 2014

Sep. 01, 2014

Jun. 01, 2014

Mar. 28, 2014

Dec. 12, 2014

Mar. 28, 2014

Mar. 28, 2014

2000 Stock Plan

2000 Stock Plan

2000 Stock Plan

2000 Stock Plan

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Statutory Stock Options

Nonstatutory Stock Options

Executive Officer

Executive Officer

Executive Officer

Member of Board of Directors [Member]

Member of Board of Directors [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

Minimum [Member]

Minimum [Member]

Member of Board of Directors [Member]

Member of Board of Directors [Member]

Member of Board of Directors [Member]

Member of Board of Directors [Member]

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

Certain Company Officers And Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option grant price, percentage of fair market value of common stock

'

'

'

'

'

100.00%

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period

'

'

'

'4 years

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'4 years

'48 months

Stock options, expiration period

'

'

'

'10 years

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options, exercised

371,348

8,333

'

125,000

8,333

'

'

'

246,348

0

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options granted, exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.88

$3.09

Stock options, shares of common stock remained outstanding

1,447,968

1,092,374

930,060

197,506

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum common stock provides for issuance under stock plan

'

'

'

0

'

'

'

3,622,983

'

'

1,322,983

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value

$0.00

$0.00

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

Additional shares available for issuance

'

'

'

'

'

'

'

2,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted share units granted

'

'

'

'

'

'

'

'

'

'

'

'

'

177,000

160,938

212,500

'

'

'

152,000

'

'

'

Fair value of restricted share units

'

'

'

'

'

'

'

'

'

'

'

'

'

$724,000

$334,000

$414,000

'

'

'

$470,000

'

'

'

Stock options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

151,500

422,000

Vesting percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

25.00%

50.00%

'

25.00%

'

'

Shares distributed

'

'

'

'

'

'

'

'

'

'

'

6,667

78,415

'

'

'

'

'

'

'

'

'

'

Valuation allowance recorded against deferred tax assets

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized compensation cost related to nonvested stock option awards

1,233,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average period over which unrecognized cost expected to be recognized

'2 years 1 month 21 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

401(k) Plan, percentage for compensation defer

90.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

401 (k) contributions

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee_Benefit_Plans_Activit

Employee Benefit Plans (Activity Related To Shares Available For Grant) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares available at beginning of period	22,471	628,675
Shares added	2,300,000	'
Options canceled	83,058	387,653
Reduction in shares reserved	-14,150	-251,058
Options granted	-810,000	-558,300
Restricted stock units canceled	'	28,001
Restricted stock units granted	-160,938	-212,500
Shares available at End of period	1,420,441	22,471
2000 Stock Plan	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options canceled	14,150	251,058
Reduction in shares reserved	-14,150	-251,058
2010 Stock Option Plan	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares available at beginning of period	22,471	628,675
Shares added	2,300,000	'
Options canceled	68,908	136,595
Options granted	-810,000	-558,300
Restricted stock units canceled	'	28,001
Restricted stock units granted	-160,938	-212,500
Shares available at End of period	1,420,441	22,471

Employee_Benefit_Plans_Summary

Employee Benefit Plans (Summary Of Stock Option Activity) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Number of Shares	'	'	'
Number of Shares Beginning Balance	1,092,374	930,060	'
Number of Shares Granted	810,000	558,300	'
Number of Shares Exercised	-371,348	-8,333	'
Number of Shares Canceled	-83,058	-387,653	'
Number of Shares Ending Balance	1,447,968	1,092,374	930,060
Number of Shares Shares exercisable	614,439	'	'
Number of Shares Shares expected to vest	683,494	'	'
Weighted Average Exercise Price	'	'	'
Weighted Average Exercise Price Beginning Balance	$4.17	$12.97	'
Weighted Average Exercise Price Granted	$2.05	$1.54	'
Weighted Average Exercise Price Exercised	$1.63	$0.75	'
Weighted Average Exercise Price Canceled	$8.66	$21.57	'
Weighted Average Exercise Price Ending Balance	$3.36	$4.17	$12.97
Weighted Average Exercise Price Shares exercisable	$5.09	'	'
Weighted Average Exercise Price Shares expected to vest	$2.08	'	'
Aggregate Intrinsic Value Beginning Balance	$20	$16	'
Aggregate Intrinsic Value Ending Balance	780	20	16
Aggregate Intrinsic Value Shares exercisable	297	'	'
Aggregate Intrinsic Value Shares expected to vest	$483	'	'
Weighted Average Remaining Contractual Term Balance	'7 years 11 months 9 days	'6 years 2 months 23 days	'5 years 10 months 24 days
Weighted Average Remaining Contractual Term Ending Balance	'7 years 11 months 9 days	'6 years 2 months 23 days	'5 years 10 months 24 days
Weighted Average Remaining Contractual Term Shares exercisable	'6 years 2 months 23 days	'	'
Weighted Average Remaining Contractual Term Shares expected to vest	'9 years 2 months 16 days	'	'

Employee_Benefit_Plans_Stock_O

Employee Benefit Plans (Stock Options Outstanding And Exercisable) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Price Lower Range	$0.01	'	'
Exercise Price Upper Range	$29.60	'	'
Options Outstanding	1,447,968	1,092,374	930,060
Weighted Average Exercise Price	$3.36	$4.17	$12.97
Weighted Average Remaining life	'7 years 11 months 9 days	'	'
Options Exercisable	614,439	'	'
Weighted Average Exercise Price	$5.09	'	'
Range One	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Price Lower Range	$0.01	'	'
Exercise Price Upper Range	$1.22	'	'
Options Outstanding	415,000	'	'
Weighted Average Exercise Price	$1.21	'	'
Weighted Average Remaining life	'9 years 29 days	'	'
Options Exercisable	87,499	'	'
Weighted Average Exercise Price	$1.15	'	'
Range Two	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Price Lower Range	$1.23	'	'
Exercise Price Upper Range	$1.62	'	'
Options Outstanding	250,012	'	'
Weighted Average Exercise Price	$1.62	'	'
Weighted Average Remaining life	'8 years 2 months 19 days	'	'
Options Exercisable	190,902	'	'
Weighted Average Exercise Price	$1.62	'	'
Range Three	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Price Lower Range	$1.63	'	'
Exercise Price Upper Range	$2.70	'	'
Options Outstanding	371,209	'	'
Weighted Average Exercise Price	$2.05	'	'
Weighted Average Remaining life	'8 years 1 month 21 days	'	'
Options Exercisable	138,172	'	'
Weighted Average Exercise Price	$2	'	'
Range Four	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Price Lower Range	$2.71	'	'
Exercise Price Upper Range	$9.92	'	'
Options Outstanding	301,949	'	'
Weighted Average Exercise Price	$4.23	'	'
Weighted Average Remaining life	'8 years 1 month 17 days	'	'
Options Exercisable	89,280	'	'
Weighted Average Exercise Price	$6.19	'	'
Range Five	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Exercise Price Lower Range	$9.93	'	'
Exercise Price Upper Range	$29.60	'	'
Options Outstanding	109,798	'	'
Weighted Average Exercise Price	$17.44	'	'
Weighted Average Remaining life	'1 year 9 months 29 days	'	'
Options Exercisable	108,586	'	'
Weighted Average Exercise Price	$17.41	'	'

Employee_Benefit_Plans_Fair_Va

Employee Benefit Plans (Fair Value of Options Vested) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Employee Benefit Plans [Abstract]	'	'
Total Intrinsic Value of Options Exercised	$291	$7
Total Fair Value of Vested Options	$550	$525

Employee_Benefit_Plans_Assumpt

Employee Benefit Plans (Assumptions used to Calculate Fair Value Of Options Granted) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Benefit Plans [Abstract]	'	'
Dividend yield	'	'
Volatility	79.00%	78.00%
Risk-free interest rate	1.91%	1.32%
Expected lives (years)	'6 years	'6 years
Weighted average fair value	$1.50	$1.04

Employee_Benefit_Plans_Allocat

Employee Benefit Plans (Allocation Of Employee Stock-Based Compensation Expense By Functional Area) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Research And Development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	$76	$127
Sales And Marketing [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	163	203
General And Administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	637	965
Employee Stock-Based Compensation [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	839	1,257
Employee Stock-Based Compensation [Member] | Research And Development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	74	112
Employee Stock-Based Compensation [Member] | Sales And Marketing [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	163	203
Employee Stock-Based Compensation [Member] | General And Administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	$602	$942

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	24 Months Ended					12 Months Ended			12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
				Research Carryforward [Member]	Development Carryforward [Member]	Federal Tax [Member]	Federal Tax [Member]	Federal Tax [Member]	State Tax [Member]	State Tax [Member]	State Tax [Member]
Income Taxes [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Operating loss, net carryforwards	'	'	'	'	'	$146,000,000	$133,000,000	'	$121,000,000	$105,000,000	'
Deferred tax assets, valuation allowance	64,346,000	57,296,000	'	'	'	'	'	'	'	'	'
Decrease in deferred tax asset, due to decrease in effective state tax	7,000,000	'	'	'	'	'	'	'	'	'	'
Deferred tax assets, research and development carryforward	'	'	'	5,655,000	5,242,000	'	'	'	'	'	'
Deferred tax assets, research and development additional credits	'	'	'	'	'	72,000	'	'	54,000	'	'
Gross unrecognized tax benefits	10,064,000	10,897,000	10,777,000	'	'	5,040,000	5,655,000	5,586,000	5,024,000	5,242,000	5,191,000
Total Unrecognized income tax benefit, affecting effective tax rate if recognized	11,000,000	'	'	'	'	'	'	'	'	'	'
Accrued interest and penalties	$0	$0	'	'	'	'	'	'	'	'	'

Income_Taxes_Domestic_And_Fore

Income Taxes (Domestic And Foreign Components Of Loss Before Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Abstract]	'	'
Domestic	($8,819)	($7,052)
Foreign	'	-94
Loss before income taxes	($8,819)	($7,146)

Income_Taxes_Components_Of_Def

Income Taxes (Components Of Deferred Tax Assets (Liabilities)) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Depreciation and amortization	$8,698	$8,955
Other	1,651	1,431
Net operating losses	54,005	46,918
Total deferred tax assets	64,354	57,304
Valuation allowance	-64,346	-57,296
Net deferred tax assets	8	8
Deferred tax liabilities:	'	'
Other	-8	-8
Total deferred tax liabilities	-8	-8
Net deferred tax asset (liability)	'	'

Income_Taxes_Reconciliation_Of

Income Taxes (Reconciliation Of Statutory Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Abstract]	'	'
Tax at federal statutory rate	34.00%	34.00%
State tax, net of federal benefit	2.00%	3.00%
Valuation allowance	-39.00%	-31.00%
Net operating loss and credit reduction due to section 382 limitations	'	-35.00%
Permanent items	-1.00%	25.00%
Other	4.00%	4.00%

Income_Taxes_Reconciliation_Of1

Income Taxes (Reconciliation Of Change In Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Contingency [Line Items]	'	'
Beginning Balance	$10,897,000	$10,777,000
Increase in tax position	126,000	120,000
Decrease due to expirations	-959,000	'
Ending Balance	10,064,000	10,897,000
Federal Tax [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Beginning Balance	5,655,000	5,586,000
Increase in tax position	72,000	69,000
Decrease due to expirations	-687,000	'
Ending Balance	5,040,000	5,655,000
State Tax [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Beginning Balance	5,242,000	5,191,000
Increase in tax position	54,000	51,000
Decrease due to expirations	-272,000	'
Ending Balance	$5,024,000	$5,242,000

Other_Related_Party_Transactio1

Other Related Party Transactions (Details) (USD $)	12 Months Ended					3 Months Ended
	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Jun. 30, 2013
	Chief Executive Officer and Director [Member]	Former President And Chief Executive Officer [Member]	Former President And Chief Executive Officer [Member]	Directors, Officers And Former Directors And Officers [Member]	Former Vice President Of Strategy [Member]	President and Chief Executive Officer [Member]
Transactions with Third Party [Line Items]	'	'	'	'	'	'
Consulting agreement fee per month	'	$18,000	'	'	'	'
Consulting service expenses	5,000	45,000	18,000	27,000	23,000	45,000
Fair value of restricted stock vested	'	'	'	$11,000	$1,000	'